Skip to main content
Log in

Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors

In the management of acute coronary syndromes

PharmacoEconomics Aims and scope Submit manuscript

Abstract

The most well established antithrombotic treatment for acute coronary syndromes (ACS) is unfractionated heparin (UFH) plus aspirin, but such treatment may not prevent arterial thrombotic events. Low molecular weight heparins (LMWHs) and platelet glycoprotein (GP) IIb/IIIa inhibitors offer alternative or adjunctive treatments. However, before these alternatives with higher acquisition costs are accepted in today’s healthcare systems, their cost effectiveness must be proven.

This paper reviews international pharmacoeconomic studies on the use of LMWHs and GP IIb/IIIa inhibitors in patients with ACS in an attempt to determine whether these therapies are cost effective. Most of the studies on LMWHs have been cost-minimisation analyses and have focused on enoxaparin sodium, because this is the only LMWH proven to be superior to UFH. Several analyses show that, compared with UFH plus aspirin, enoxaparin sodium provides cost savings both during hospitalisation (30 days) and 1-year follow-up. These cost savings are mainly attributable to fewer cardiac interventions, shorter hospital stays and lower administrative costs. Indeed, the clinical and economic advantages of enoxaparin sodium have led to its recommendation in recent guidelines as the antithrombotic agent of choice for coronary artery disease.

Most of the economic analyses of GP IIb/IIIa inhibitors have been cost-effectiveness analyses. Such analyses indicate that the high acquisition costs of these drugs may be at least partially offset by reductions in other costs if a noninvasive approach to risk stratification is used. Furthermore, use of GP IIb/IIIa inhibitors appears to give favourable cost-effectiveness ratios compared with other accepted therapies, such as fibrin-specific thrombolytic therapy, in the cardiovascular field, particularly in high-risk patients and those undergoing percutaneous coronary intervention. However, more comprehensive economic data on the GP IIb/IIIa inhibitors are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III
Table IV

Notes

  1. The use of tradenames is for product identification purposes only and does not imply endorsement.

References

  1. Hirsh PD, Hillis LD, Campbell WB, et al. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischaemic heart disease. N Engl J Med 1981; 304: 685–91

    Article  PubMed  CAS  Google Scholar 

  2. Hamm CW, Lorenz RL, Bleifeld W, et al. Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol 1987; 10: 988–1004

    Article  Google Scholar 

  3. Fuster V, Lewis A. Conner Memorial lecture: mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994; 90: 2126–46

    Article  PubMed  CAS  Google Scholar 

  4. US Department of Health and Human Services, National Center for Health Statistics. Detailed diagnoses and procedures. In: National Hospital Discharge Survey, 1996. Hyattsville (MD): US Department of Health and Human Services, National Center for Health Statistics, 1998: 13

    Google Scholar 

  5. Fox KAA, Goodman SG, Klein W, et al. for the GRACE Investigators. Management of acute coronary syndromes: vari-ations in practice and outcome: findings from the Global Registry of Acute Coronary Events (GRACE). Fur Heart J 2002; 23: 1177–89

    Article  CAS  Google Scholar 

  6. Collinson J, Flather MD, Fox KAA, et al. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK). Fur Heart J 2000; 21: 1450–7

    Article  CAS  Google Scholar 

  7. Braunwald E, Amman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Circulation 2002 Oct 1; 106 (14): 1893–900

    Article  PubMed  Google Scholar 

  8. Théroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105–11

    Article  PubMed  Google Scholar 

  9. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–30

    Article  Google Scholar 

  10. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 1994; 89: 81–8

    Article  PubMed  CAS  Google Scholar 

  11. Oler A, Whooley MA, Oler J, et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA 1996; 276: 811–5

    Article  PubMed  CAS  Google Scholar 

  12. Hirsh J. Low-molecular-weight heparin: a review of the results of recent studies on the treatment of venous thromboembolism and unstable angina. Circulation 1998; 98: 1575–82

    Article  PubMed  CAS  Google Scholar 

  13. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114 (5 Suppl.): 489S–510S

    Article  PubMed  CAS  Google Scholar 

  14. Théroux P, Waters D, Lam J, et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992; 327: 141–5

    Article  PubMed  Google Scholar 

  15. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631–7

    Article  Google Scholar 

  16. Metz BK, White HD, Granger CB, et al. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: re sults from the GUSTO-IIb Trial. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. J Am Coll Cardiol 1998; 31: 1493–8

    Article  PubMed  CAS  Google Scholar 

  17. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial in farction, refractory angina, and revascularisation procedures in patients with acute myocardial ischemia without ST elevation: a randomised trial. Lancet 1999; 353: 429–38

    Article  Google Scholar 

  18. Barrowcliffe TW, Johnson EA, Thomas DP. Low molecular weight heparin. Chichester: John Wiley & Sons, 1992

    Google Scholar 

  19. Bounameaux H. Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic disease. New York (NY): Marcel Dekker, 1994

    Google Scholar 

  20. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688–98

    Article  PubMed  CAS  Google Scholar 

  21. Bertrand ME, Simoons ML, Fox KAA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force on the Manage ment of Acute Coronary Syndromes of the European Society of Cardiology. Fur Heart J 2002; 23: 1809–40

    Article  Google Scholar 

  22. Lynch Jr JJ, Cook JJ, Sitko GR, et al. Nonpeptide glycoprotein IIb/IIIa inhibitors: 5. antithrombotic effects of MK-0383. J Pharmacol Exp Ther 1995; 272: 20–32

    PubMed  CAS  Google Scholar 

  23. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for un-stable coronary artery disease: Efficacy and Safety of Subcuta neous Enoxaparin in Non-Q-Wave Coronary Events Group. N Engl J Med 1997; 337: 447–52

    Article  PubMed  CAS  Google Scholar 

  24. Antman EM, McCabe CH, Gurfinkel EP, et al., for the TIMI 11B Investigators. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial in farction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100: 1593–601

    Article  PubMed  CAS  Google Scholar 

  25. Antman EM, Cohen M, Radley D, et al., for the TIMI IIB and ESSENCE Investigators. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial in farction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999; 100: 1602–8

    Article  PubMed  CAS  Google Scholar 

  26. Antman EM, Cohen M, McCabe C, et al., for the TIMI 11B and ESSENCE Investigators. Enoxaparin is superior to unfraction-ated heparin for preventing clinical events at 1-year follow up of TIMI I 1B and ESSENCE. Fur Heart J 2002; 23: 308–14

    Article  CAS  Google Scholar 

  27. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI I 1A. J Am Coll Cardiol 1997; 29: 1474–82

    Article  Google Scholar 

  28. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995; 26: 313–8

    Article  PubMed  CAS  Google Scholar 

  29. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561–8

    Google Scholar 

  30. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997; 96: 61–8

    Article  PubMed  CAS  Google Scholar 

  31. The FRAXIS Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAXIS (FRAXiparine in Ischaemic Syndrome). Fur Heart J 1999; 20: 1553–62

    Article  Google Scholar 

  32. Detoumay B, Huet X, Fagnani F, et al. Economic evaluation of enoxaparin sodium vs heparin in unstable angina: a French sub-study of the ESSENCE trial. Pharmacoeconomics 2000; 18 (1): 83–9

    Article  Google Scholar 

  33. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low molecular weight heparin (enoxaparin) vs unfractionated heparin in acute coronary syndrome patients. Results from the ESSENCE randomized trial. Circulation 1998; 97: 1702–7

    Article  PubMed  CAS  Google Scholar 

  34. Fox KAA, Bosanquet N. Assessing the UK cost implications of the use of low molecular weight heparin in unstable coronary artery disease. Br J Cardiol 1998; 5: 95–105

    Google Scholar 

  35. Balen RM, Marra CA, Zed PJ, et al. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes: a Canadian hospital perspective. Pharmacoeconomics 1999; 16 (5 Pt 2): 533–42

    Article  PubMed  CAS  Google Scholar 

  36. Bozovich G, Gurfinkel E, Barreiro D, et al. Reduction of hospital costs for patients with acute non-Q-wave myocardial infarction or unstable angina treated with enoxaparin compared to standard heparin [abstract]. Fur Heart J 1999; 20: 545

    Google Scholar 

  37. Bosanquet N, Fox KAA. Longer-term economic benefits reflect improved clinical outcomes with enoxaparin versus unfractionated heparin in acute coronary syndromes: one-year data. Br J Cardiol 2001; 8: 36–7

    Google Scholar 

  38. O’Brien BJ, Willan A, Blackhouse G, et al. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? Am Heart J 2000; 139: 423–9

    PubMed  Google Scholar 

  39. Harrington RA. Overview of clinical trials of glycoprotein IIb–IIIa inhibitors in acute coronary syndromes. Am Heart J 1999; 138: 276–86

    Article  PubMed  CAS  Google Scholar 

  40. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. International, randomized, controlled trial of lamifiban (a platelet glycoprotein Ilb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998; 97: 2386–95

    Article  Google Scholar 

  41. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498–505

    Article  Google Scholar 

  42. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488–97

    Article  Google Scholar 

  43. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein Ilb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436–43

    Article  Google Scholar 

  44. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330: 956–61

    Article  Google Scholar 

  45. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997; 349: 1429–35

    Article  Google Scholar 

  46. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689–96

    Article  Google Scholar 

  47. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-Ilb/IIIa blockade: evaluation of Platelet Ilb/IIIa Inhibitor for Stenting. Lancet 1998; 352: 87–92

    Article  Google Scholar 

  48. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascu larisation: the GUSTO IV-ACS randomised trial. Lancet 2001; 357: 1915–24

    Article  Google Scholar 

  49. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998; 98: 2829–35

    Article  PubMed  CAS  Google Scholar 

  50. Mark DB, Harrington RA, Lincoff AM, et al. Cost-effectiveness of platelet glycoprotein Ilb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 2000; 101: 366–71

    Article  PubMed  CAS  Google Scholar 

  51. Henderson RA, Brown R. The costs of routine eptifibatide use in acute coronary syndromes in Western Europe: an economic substudy of the PURSUIT trial. Fur Heart J 1999; Suppl. 1: 35N–41N

    Google Scholar 

  52. Mark DB, Talley JD, Topol EJ, et al., for the EPIC Investigators. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. Circulation 1996; 94: 629–35

    Article  PubMed  CAS  Google Scholar 

  53. Lincoff AM, Mark DB, Tcheng JE, et al. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Circulation 2000; 102: 2923–9

    Article  PubMed  CAS  Google Scholar 

  54. Weintraub WS, Culler S, Boccuzzi SJ, et al. Economic impact of GPIIb/IIIa blockade after high-risk angioplasty: results from the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. J Am Coll Cardiol 1999; 34: 1061–6

    Article  PubMed  CAS  Google Scholar 

  55. Cohen DJ, O’Shea JC, Pacchiana CM, et al. In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT trial). Am J Cardiol 2002; 89: 61–4

    Article  PubMed  Google Scholar 

  56. Hillegass WB, Newman AR, Raco DL. Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST segment elevation acute coronary syndromes: estimat ing the economic implications. Pharmacoeconomics 2001; 19: 41–55

    Article  PubMed  CAS  Google Scholar 

  57. Brown RE, Henderson RA, Koster D, et al. Cost-effectiveness of eptifibatide in acute coronary syndromes: an economic analysis of Western European patients enrolled in the PURSUIT trial. Eur Heart J 2002; 23: 50–8

    Article  PubMed  CAS  Google Scholar 

  58. van Hout BA, Simoons ML. Costs and effects of c7E3 in high risk PTCA patients: an indirect analysis for the Netherlands. Eur Heart J 1995; 16 Suppl. L: 81–5

    Article  PubMed  Google Scholar 

  59. Bowman L, van Hout BA. Cost effectiveness of abciximab at 1 year in the Netherlands [abstract]. Am J Cardiol 1997; 80 Suppl. 7A: 625

    Google Scholar 

  60. Bala MV, Anderson KM, Barber BL. Abciximab is cost-effective in patients undergoing percutaneous coronary intervention with stents [abstract]. J Am Coll Cardiol 1999; 33 Suppl. A: 15A

    Google Scholar 

  61. The RESTORE Investigators. Effects of platelet glycoprotein Ilb/IIIa blockade with frofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445–53

    Article  Google Scholar 

  62. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000; 356: 2037–44

    Article  Google Scholar 

  63. Zwart-van Rijkom JEF, Klungel OH, Leufkens HGM, et al. Costs and effects of combining stenting and abciximab (ReoPro®) in daily practice. Int J Cardiol 2001; 77: 299–303

    Article  PubMed  CAS  Google Scholar 

  64. Zwart-van Rijkom JEF, van Hout BA. Cost-efficacy in interventional cardiology: results from the EPISTENT study. Eur Heart J 2001; 22: 1476–84

    Article  Google Scholar 

  65. Cannon CP, Weintraub WS, Demopoulos LA, et al. for the TACTICS-TIMI 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coro nary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879–87

    Article  PubMed  CAS  Google Scholar 

  66. Mahoney EM, Cannon CP, Jurkovitz CT, et al. Long-term cost-effectiveness of an early invasive strategy for the treatment of unstable angina and non-ST elevation myocardial infarction. Circulation 2002; 106: 11–758, 3722

    Article  Google Scholar 

  67. Hamm CW, Heeschen C, Goldmann B, et al., for the CAPTURE Study Investigators. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999; 340: 1623–9

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Aventis Pharmaceuticals, Bridgewater, NJ, USA, provided an educational grant for a literature search for this review article. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bosanquet, N., Jönsson, B. & Fox, K.A.A. Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors. Pharmacoeconomic 21, 1135–1152 (2003). https://doi.org/10.2165/00019053-200321160-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200321160-00001

Keywords

Navigation